Products — Magnus Veritas Medical Technologies (MVMT)

Orthobiologics

Regenerative solutions for healing and repair.

Orthobiologics are biological materials used in modern surgical practice to promote faster, more natural healing. Mesenchymal stem cell (MSC) therapy is one of the core tools in that category, harnessing the body's own regenerative capacity to repair damaged tissue. The two primary sources are bone marrow, drawn from the iliac crest where MSC concentration is highest, and adipose tissue, which can be harvested through a minimally invasive, low-risk procedure. These therapies apply across orthopaedics, spinal surgery, maxillofacial surgery, pain management, wound healing, and general or urogynecological surgery.

01 / Bone Growth Stimulation

Signal the body to heal faster.

A continuously wearable bone growth stimulation system built to fit into a patient's day rather than interrupt it, compact enough to clip on a belt or tuck into a pocket, with no restricted postures and no scheduled sessions. Built-in sensors and a proprietary algorithm track wear time and relative activity level automatically, combined with patient-reported pain scores in a companion app for a clear day-to-day view of recovery. Clinicians get that same picture through a remote portal that flags patients whose progress may be falling off track. In a Level 1 clinical study, the therapeutic signal was associated with a 31% increase in fusion success regardless of fusion type, a 2.33x greater likelihood of a successful outcome, and a 56% reduction in failure rates, evaluated using both radiographic and clinical evidence rather than radiographic evidence alone. Preclinical data also shows increasing bone cell proliferation the longer the device is worn each day, consistent with a dose-dependent response.

Mechanism: continuous electrical stimulation of osteogenesis, wear-time linked dosing

02 / Bone Marrow Aspiration

The patient's own biology, put to work.

A point-of-care aspiration system that harvests and concentrates a patient's own mesenchymal stem cells at the bedside, no centrifuge, no lab transfer, no added staff or setup time. A closed-tip trocar design with micrometric lateral aspiration draws marrow cells while minimizing dilution from peripheral blood, maximizing cellular yield per pass. The concentrated aspirate can be combined with a bone graft substitute to accelerate healing toward a more vascularized, regenerative result.

Mechanism: selective marrow aspiration, autologous MSC concentration

03 / Synthetic Osteoconductive Scaffold

A structure for new bone to grow through.

A non-mineralized, synthetic bone void filler built from a highly porous polymer scaffold (75–95% total porosity, with macropores 100–500 μm and micropores under 100 μm) engineered to give cells a structure to infiltrate and build on. Placed in direct contact with patient bone, it supports and guides new bone ingrowth across the graft site and is fully resorbed as healing progresses, replaced by the patient's own bone. It starts radiolucent and becomes radiopaque as fusion occurs, so surgeons can visualize healing in real time and catch pseudoarthrosis early. Fully synthetic with no disease-transmission risk, and compressible enough to pack into a void or suture in place. Available in block, granulate, and cube forms.

Mechanism: osteoconductive polymer scaffold, resorbable

04 / PRP & Regenerative Injection

Concentrated healing, injected where it's needed.

A benchtop processing system that captures the buffy coat through a simple push method, with clear volume markings for consistent, reproducible results. A single 10-minute spin, fewer steps than most systems on the market, prepared chairside from the patient's own blood draw. A typical 60 mL draw yields roughly 6.3 mL of PRP and an average of 10.8 billion platelets in a single dose. Leukocyte concentration is tailorable, the volume of enriched plasma, buffy coat, and white blood cells can be adjusted to fit the individual patient and pathology. In an independent, peer-reviewed clinical evaluation of 70 consecutive samples across two outpatient sites, the single-spin process delivered an 83% platelet capture rate and up to 10x platelet concentration over baseline, while producing PRP formulations across a range of leukocyte profiles without sacrificing platelet yield. Fewer transfer steps also means less mechanical trauma to cells and lower contamination risk.

Mechanism: single-spin platelet concentration, 83% capture rate

Building your territory? We're always evaluating new technologies for the catalog. Full specs, manufacturer detail, and pricing are shared directly upon inquiry.

Ask About a Product

Five technologies, one goal.

Regenerative solutions for healing and repair.

Signal the body to heal faster.

The patient's own biology, put to work.

A structure for new bone to grow through.

Concentrated healing, injected where it's needed.

Imaging that goes wherever the patient does.